selpercatinib
eli lilly
['libretto-001']
join us at #esmo22 - we re presenting updated efficacy and safety analysis with more mature follow-up from libretto-001, a trial investigating a selective ret inhibitor in patients with ret-mutant medullary #thyroidcancer. view the presentation: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK